drugset / Trial / NCT07531095
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
Timeline
- Start
- 2026-04-21
- Primary completion
- 2028-05-21
- Completion
- 2031-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Tarlatamab | Protein / enzyme biologic | — | Intravenous |
| Subject | ZL-1310 | Other / unclassified | — | Intravenous |